In SCCHN, EGFR and its ligand, TGF-α, are overexpressed in 80–90% of cases; the corresponding magnitudes of increase are 1.7-fold (P = 0.005) and 1.9-fold (P = 0.006) respectively, when compared to controls [14]. Here, EGFR is linked to head and neck squamous cell carcinoma.